The Rise of Synaptic Density PET Imaging

[en] Many neurological disorders are related to synaptic loss or pathologies. Before the boomof positrons emission tomography (PET) imaging of synapses, synaptic quantification could onlybe achievedin vitroon brain samples after autopsy or surgical resections. Until the mid-2010s,electron microscopy and immunohistochemical labelling of synaptic proteins were the gold-standardmethods for such analyses. Over the last decade, several PET radiotracers for the synaptic vesicle 2Aprotein have been developed to achievein vivosynapses visualization and quantification. Differentstrategies were used, namely radiolabelling with either11C or18F, preclinical development in rodentand non-human primates, and binding quantification with different kinetic modelling methods. Thisreview provides an overview of these PET tracers and underlines their perspectives and limitationsby focusing on radiochemical aspects, as well as preclinical proof-of-concept and the main clinicaloutcomes described so far.

Disciplines :

Neurology

Author, co-author :

Becker, Guillaume ; Université de Liège - ULiège > Département de Psychologie > Département de Psychologie

Dammicco, Sylvestre ; Université de Liège - ULiège > GIGA CRC In vivo Imaging - Radiochemistry

Bahri, Mohamed Ali ; Université de Liège - ULiège > GIGA CRC In vivo Imaging - Aging & Memory

SALMON, Eric ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Centre de jour interdisciplinaire des troubles de la mémoire

Language :

English

Title :

The Rise of Synaptic Density PET Imaging

Publication date :

14 May 2020

Journal title :

Molecules

eISSN :

1420-3049

Publisher :

Multidisciplinary Digital Publishing Institute (MDPI), Switzerland

Volume :

25, 2303

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 05 February 2021

Statistics

Number of views

73 (9 by ULiège)

Number of downloads

3 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Lynch B.A.; Lambeng, N., Nocka, K.; Kensel-Hammes, P.; Bajjalieh, S.M.; Matagne, A.; Fuks, B. The Synaptic Vesicle Protein Sv2a Is the Binding Site for the Antiepileptic Drug Levetiracetam. Proc. Natl. Acad. Sci. USA, 2004, 101, 9861–9866.
Bajjalieh, S.M.; Frantz, G.D.; Weimann, J.M.; McConnell, S.K.; Scheller, R.H. Differential Expression of Synaptic Vesicle Protein 2 (Sv2) Isoforms. J. Neurosci. 1994, 9 5223–5235.
Crowder, K.M.; Gunther, J.M.; Jones, T.A.; Hale, B.D.; Zhang, H.Z.; Peterson, M.R.; Scheller, R.H.; Chavkin, C.; Bajjalieh, S.M. Abnormal Neurotransmission in Mice Lacking Synaptic Vesicle Protein 2a (Sv2a). Proc. Natl. Acad. Sci. U S A, 1999, 26, 15268–15273.
Bartholome, O.; Van den Ackerveken, P.; Sánchez Gil, J; de la Brassinne Bonardeaux, O.; Leprince,P.; Franzen, R.; Rogister, B. Puzzling out Synaptic Vesicle 2 Family Members Functions. Front. Mol. Neurosci., 2017, 148, doi.org/10.3389/fnmol.2017.00148
Bakker, A.; Krauss, G.L.; Albert, M.S.; Speck, C.L.; Jones, L.R.; Stark, C.E.; Yassa, M.A.; Bassett, S.S.; Shelton, A.L.; Gallagher, M. Reduction of Hippocampal Hyperactivity Improves Cognition in Amnestic Mild Cognitive Impairment. Neuron., 2012, 3, 467–474.
Pascal, E.S.; Zhu, L.; Verret, L.; Vossel, K.A.; Orr, A.G.; Cirrito, J.R.; Devidze, N.; Ho, K.; Yu,G.-Q.; Palop, J.J.; Mucke, L. Levetiracetam Suppresses Neuronal Network Dysfunction and Reverses Synaptic and Cognitive Deficits in an Alzheimer’s Disease Model. Proceedings of the National Academy of Sciences 109, 2012, 42, E2895–E2903.
Terry, R.D.; Masliah, E.; Salmon, D.P.; Butters, N.; DeTeresa, R.; Hill, R.; Hansen, L.A.; Katzman, R. Physical Basis of Cognitive Alterations in Alzheimer’s Disease: Synapse Loss Is the Major Correlate of Cognitive Impairment. Ann. Neurol., 1991, 4, 572–580.
Scheff, S.W.; Price, D.,A.; Schmitt, F.A.; Mufson, E.J. Hippocampal Synaptic Loss in Early Alzheimer’s Disease and Mild Cognitive Impairment. Neurobiology of Aging, 2006, 10, 1372–1384.
Klitgaard, H. and Verdu, P. Levetiracetam: the First Sv2a Ligand for the Treatment of Epilepsy. 2007, 2, 11, doi: 10.1517/17460441.2.11.1537.
Gillard, M., Fuks, B.; Michel, P.; Vertongen, P.; Massingham, R.; Chatelain, P. Binding Characteristics of [3h]Ucb 30889 to Levetiracetam Binding Sites in Rat Brain. Eur. J. Pharmacol., 2003, 478, 1–9.
Klitgaard, H.; Matagne, A.; Gobert, J.; Wulfert, E. Evidence for a Unique Profile of Levetiracetam in Rodent Models of Seizures and Epilepsy. Eur. J. Pharmacol., 1998, 353, 191–206.
Gillard, M.; Fuks, B.; Leclercq, K.; Matagne, A. Binding Characteristics of Brivaracetam, a Selective, High Affinity Sv2a Ligand in Rat, Mouse and Human Brain: Relationship to Anti-Convulsant Properties. Eur. J. Pharmacol., 2011, 664, 36–44.
Mercier, J.; Archen, L.; Bollu, V.; Carré, S.; Evrard, Y.; Jnoff, E.; Kenda, B.; Lallemand, B.; Michel, P.; Montel, F.; Moureau, F.; Price, N.; Quesnel, Y.; Sauvage, X.; Valade, A.; Provins, L. Discovery of Heterocyclic Nonacetamide Synaptic Vesicle Protein 2a (Sv2a) Ligands with Single-Digit Nanomolar Potency: Opening Avenues Towards the First Sv2a Positron Emission Tomography (Pet) Ligands. Chem. Med. Chem., 2014, 9, 693–698.
Zhang, L.; Villalobos, A. Strategies to Facilitate the Discovery of Novel Cns Pet Ligands. EJNMMI Radiopharm. Chem., 2017, 13, doi: 10.1186/s41181-016-0016-2.
Need, A.; Kant, N.; Jesudason, C.; Barth, V. Approaches for the Discovery of Novel Positron Emission Tomography Radiotracers for Brain Imaging. Clinical and Translational Imaging, 2017, 5, 265–274.
Pike, V.W. Considerations in the Development of Reversibly Binding Pet Radioligands for Brain Imaging. Current medicinal chemistry, 2016, 18, 1818–1869.
Zhang, L., Villalobos, A.; Beck, E.M.; Bocan, T.; Chappie, T.A.; Chen, L.; Grimwood, S.; Heck, S.D.; Helal, C.J.; Hou, X.; Humphrey, J.M.; Lu, J.; Skaddan, M.B.; McCarthy, T.J.; Verhoest, P.R.; Wager, T.T.; Zasadny,K. Design and Selection Parameters to Accelerate the Discovery of Novel Central Nervous System Positron Emission Tomography (Pet) Ligands and Their Application in the Development of a Novel Phosphodiesterase 2a Pet Ligand. J. Med. Chem., 2013, 56, 4568–4579.
Hancheng, C.; Mangner, T.J.; Muzik, O.; Wang, M.-W.; Chugani, D.C.; Chugani, H.T. Radiosynthesis of (11)C-Levetiracetam: A Potential Marker for Pet Imaging of Sv2a Expression. ACS Medicinal Chemistry Letters, 2014, 10, 1152–1155.
Warnock, G.I.; Aerts, J.; Bahri, M.A.; Bretin, F.; Lemaire, C.; Giacomelli, F.; Mievis, F.; Mestdagh, N.; Buchanan, T.; Valade, A.; Mercier, J.; Wood, M.; Gillard, M.; Seret, A.; Luxen, A.; Salmon, E.; Plenevaux, A. Evaluation of 18f-Ucb-H as a Novel Pet Tracer for Synaptic Vesicle Protein 2a in the Brain. J. Nucl. Med., 2014, 8, 1336–1341.
Aerts, J.; Otabashi, M.; Giacomelli, F.; Warnock, G.; Bahri, M.; Bretin, F.; Sauvage, X.; Thielen, C.; Lemaire, C.; Salmon, E.; Plenevaux, A.; Luxen, A. Radiosynthesis and First Small Animal Micropet Imaging of [18f]Ucb-H, a New Fluorine-18 Labelled Tracer Targeting Synaptic Vesicle Protein 2a (Sv2a). EANM Abstracts, 2013, 40, S158. http://hdl.handle.net/2268/163936
Warnier, C.; Lemaire, C.; Becker, G.; Zaragoza, G.; Giacomelli, F.; Aerts, J.; Otabashi, M.; Bahri, M.A.; Mercier, J.; Plenevaux, A.; Luxen, A. Enabling Efficient Positron Emission Tomography (Pet) Imaging of Synaptic Vesicle Glycoprotein 2a (Sv2a) with a Robust and One-Step Radiosynthesis of a Highly Potent 18f-Labeled Ligand ([18f]Ucb-H). J. Med. Chem., 2016, 59, 8955–8966.
Pike, V.W.; Aigbirhio, F.I. Reactions of Cyclotron-Produced [18f] Fluoride with Diaryliodonium Salts—a Novel Single-Step Route to No-Carrier-Added [18] Fluoroarenes. J. Chem. Soc., Chemical Communications, 1995, 21, 2215–2216.
Estrada, S.; Lubberink, M.; Thibblin, A.; Sprycha, M.; Buchanan, T.; Mestdagh, N.; Kenda, B.; Mercier, J.; Provins, L.; Gillard, M.; Tytgat, D.; Antoni, G. [11c]Ucb-a, a Novel Pet Tracer for Synaptic Vesicle Protein 2a. Nucl. Med. Biol., 2016, 43, 325–332.
Nabulsi, N.B.; Mercier, J.; Holden, D.; Carre, S.; Najafzadeh, S.; Vandergeten, M.C.; Lin, S.F.; Deo, A.; Price, N.; Wood, M.; Lara-Jaime, T.; Montel, F.; Laruelle, M.; Carson, R.E.; Hannestad, J.; Huang, Y. Synthesis and Preclinical Evaluation of 11c-Ucb-J as a Pet Tracer for Imaging the Synaptic Vesicle Glycoprotein 2a in the Brain. J.Nucl.Med., 2016, 57, 777–784.
Rokka, J.; Schlein, E.; Eriksson, J. Improved synthesis of SV2A targeting radiotracer [11C]UCB-J. EJNMMI Radiopharm. Chem. 2019, 4, doi:10.1186/s41181-019-0080-5.
Sephton, S.M.; Miklovicz, T.; Russell, J.J.; Doke, A.; Li, L.; Boros, I.; Aigbirhio, F.I. Automated radiosynthesis of [11C]UCB-J for imaging synaptic density by positron emission tomography. J. Label. Compd. Radiopharm. 2020, 63, 151–158.
Li, S.; Cai, Z.; Zhang, W.; Holden, D.; Lin, S.-F.; Finnema, S.J.; Shirali, A.; Ropchan, J.; Carre, S.; Mercier, J.; et al. Synthesis and in vivo evaluation of [18F]UCB-J for PET imaging of synaptic vesicle glycoprotein 2A (SV2A). Eur. J. Nucl. Med. Mol. Imaging 2019, 46, 1952–1965.
Li, S.; Cai, Z.; Wu, X.; Holden, D.; Pracitto, R.; Kapinos, M.; Gao, H.; Labaree, D.C.; Nabulsi, N.; Carson, R.E.; et al. Synthesis and in Vivo Evaluation of a Novel PET Radiotracer for Imaging of Synaptic Vesicle Glycoprotein 2A (SV2A) in Nonhuman Primates. ACS Chem. Neurosci. 2018, 10, 1544–1554.
Constantinescu, C.C.; Tresse, C.; Zheng, M.; Gouasmat, A.; Carroll, V.M.; Mistico, L.; Alagille, D.; Sandiego, C.M.; Papin, C.; Marek, K.; et al. Development and In Vivo Preclinical Imaging of Fluorine-18-Labeled Synaptic Vesicle Protein 2A (SV2A) PET Tracers. Mol. Imaging Boil. 2018, 21, 509–518.
Cai, Z.; Li, S.; Finnema, S.; Lin, S.; Zhang, W.; Holden, D.; Carson, R.; Huang, Y. Imaging Synaptic Density with Novel 18f-Labeled Radioligands for Synaptic Vesicle Protein-2a (Sv2a): Synthesis and Evaluation in Nonhuman Primates. J. Nucl. Med. 2017, 58, S1, 547.
Cai, Z.; Li, S.; Zhang, W.; Pracitto, R.; Wu, X.; Baum, E.; Finnema, S.J.; Holden, D.; Toyonaga, T.; Lin, S.-F.; et al. Synthesis and Preclinical Evaluation of an 18F-Labeled Synaptic Vesicle Glycoprotein 2A PET Imaging Probe: [18F]SynVesT-2. ACS Chem. Neurosci. 2020, 11, 592–603.
Patel, S.; Knight, A.; Krause, S.; Teceno, T.; Tresse, C.; Li, S.; Cai, Z.; Gouasmat, A.; Carroll, V.M.; Barret, O.; et al. Preclinical In Vitro and In Vivo Characterization of Synaptic Vesicle 2A-Targeting Compounds Amenable to F-18 Labeling as Potential PET Radioligands for Imaging of Synapse Integrity. Mol. Imaging Biol. 2019, 1–10, doi:10.1007/s11307-019-01428-0.
Trump, L.; Lemos, A.; Lallemand, B.; Pasau, P.; Mercier, J.; Lemaire, C.; Luxen, A.; Genicot, C. Late-Stage 18f-Difluoromethyl Labeling of N-Heteroaromatics with High Molar Activity for Pet Imaging. Angew. Chem., Int. Ed. 2019, 131, 13283–13288
Trump, L.; Lemos, A.; Jacq, J.; Pasau, P.; Lallemand, B.; Mercier, J.; Genicot, C.; Luxen, A.; Lemaire, C. Development of a General Automated Flow Photoredox 18F-Difluoromethylation of N-Heteroaromatics in an AllinOne Synthesizer. Org. Process. Res. Dev. 2020, doi:10.1021/acs.oprd.9b00442
Serrano, M.E.; Becker, G.; Bahri, M.A.; Seret, A.; Mestdagh, N.; Mercier, J.; Mievis, F.; Giacomelli, F.; Lemaire, C.; Salmon, E.; et al. Evaluating the In Vivo Specificity of [18F]UCB-H for the SV2A Protein, Compared with SV2B and SV2C in Rats Using microPET. Mol. 2019, 24, 1705.
Bretin, F.; I.; Warnock, G.; Bahri, M.A.; Aerts, J.; Mestdagh, N.; Buchanan, T.; Valade, A.; Mievis, F.; Giacomelli, F.; Lemaire, C.; et al. Preclinical radiation dosimetry for the novel SV2A radiotracer [18F]UCB-H. EJNMMI Res. 2013, 3, 35, doi:10.1186/2191-219X-3-35.
Becker, G.; Warnier, C.; Serrano, M.E.; Bahri, M.A.; Mercier, J.; Lemaire, C.; Salmon, E.; Luxen, A.; Plenevaux, A. Pharmacokinetic Characterization of [18F]UCB-H PET Radiopharmaceutical in the Rat Brain. Mol. Pharm. 2017, 14, 2719–2725.
Serrano, M.E.; Bahri, M.A.; Becker, G.; Seret, A.; Mievis, F.; Giacomelli, F.; Lemaire, C.; Salmon, E.; Luxen, A.; Plenevaux, A. Quantification of [18F]UCB-H Binding in the Rat Brain: From Kinetic Modelling to Standardised Uptake Value. Mol. Imaging Boil. 2018, 21, 888–897.
Serrano, M.E.; Bahri, M.A.; Becker, G.; Seret, A.; Germonpré, C.; Lemaire, C.; Giacomelli, F.; Mievis, F.; Luxen, A.; Salmon, E.; et al. Exploring with [18F]UCB-H the in vivo Variations in SV2A Expression through the Kainic Acid Rat Model of Temporal Lobe Epilepsy. Mol. Imaging Boil. 2020, 1–11, doi:10.1007/s11307-020-01488-7.
Finnema, S.J.; Nabulsi, N.B.; Eid, T.; Detyniecki, K.; Lin, S.F.; Chen, M.-K.; Dhaher, R.; Matuskey, D.; Baum, E.; Holden, D.; et al. Imaging synaptic density in the living human brain. Sci. Transl. Med. 2016, 8, 348ra96.
Toyonaga, T.; Smith, L.M.; Finnema, S.J.; Gallezot, J.D.; Naganawa, M.; Bini, J.; Mulnix, T.; Cai, Z.; Ropchan, J.; Huang, Y.; et al. In Vivo Synaptic Density Imaging with 11C-UCB-J Detects Treatment Effects of Saracatinib in a Mouse Model of Alzheimer Disease. J. Nucl. Med. 2019, 60, 1780–1786
Nicolas, J.M.; Hannestad, J.; Holden, D.; Kervyn, S.; Nabulsi, N.; Tytgat, D.; Huang, Y.; Chanteux, H.; Staelens, L.; Matagne, A.; et al. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action. Epilepsia 2015, 57, 201–209.
Bahri, M.A.; Plenevaux, A.; Aerts, J.; Bastin, C.; Becker, G.; Mercier, J.; Valade, A.; Buchanan, T.; Mestdagh, N.; LeDoux, D.; et al. Measuring brain synaptic vesicle protein 2A with positron emission tomography and [18 F]UCB-H. Alzheimer’s Dementia: Transl. Res. Clin. Interv. 2017, 3, 481–486.
Bastin, C.; Bahri, M.A.; Meyer, F.; Manard, M.; Delhaye, E.; Plenevaux, A.; Becker, G.; Seret, A.; Mella, C.; Giacomelli, F.; et al. In vivo imaging of synaptic loss in Alzheimer’s disease with [18F]UCB-H positron emission tomography. Eur. J. Nucl. Med. Mol. Imaging 2019, 47, 390–402.
Salinas, C.A.; Searle, G.E.; Gunn, R.N. The simplified reference tissue model: model assumption violations and their impact on binding potential. Br. J. Pharmacol. 2014, 35, 304–311.
Wahlund, L.O.; Barkhof, F.; Fazekas, F.; Bronge, L.; Augustin, M.; Sjögren, M.; Wallin, A.; Ader, H.; Leys, D.; Pantoni, L.; et al. A New Rating Scale for Age-Related White Matter Changes Applicable to MRI and CT. Stroke 2001, 32, 1318–1322.
Schain, M.; Benjaminsson, S.; Varnäs, K.; Forsberg, A.; Halldin, C.; Lansner, A.; Farde, L.; Varrone, A. Arterial input function derived from pairwise correlations between PET-image voxels. Br. J. Pharmacol. 2013, 33, 1058–1065
Rousset, O.G.; Ma, Y.; Evans, A.C. Correction for partial volume effects in PET: principle and validation. J. Nucl. Med. 1998, 39, 904–911.
Erlandsson, K.; Buvat, I.; Pretorius, P.H.; Thomas, B.A.; Hutton, B.F. A review of partial volume correction techniques for emission tomography and their applications in neurology, cardiology and oncology. Phys. Med. Boil. 2012, 57, R119–R159.
Thomas, B.A.; Cuplov, V.; Bousse, A.; Mendes, A.; Thielemans, K.; Hutton, B.F.; Erlandsson, K. PETPVC: a toolbox for performing partial volume correction techniques in positron emission tomography. Phys. Med. Boil. 2016, 61, 7975–7993.
Tzourio-Mazoyer, N.; Landeau, B.; Papathanassiou, D.; Crivello, F.; Etard, O.; Delcroix, N.; Mazoyer, B.; Joliot, M. Automated Anatomical Labeling of Activations in SPM Using a Macroscopic Anatomical Parcellation of the MNI MRI Single-Subject Brain. NeuroImage 2002, 15, 273–289.
Wu, Y.; Carson, R.E. Noise Reduction in the Simplified Reference Tissue Model for Neuroreceptor Functional Imaging. J. Cereb. Blood. Flow Metab. 2002, 22, 1440–52.
Rossano, S.; Toyonaga, T.; Finnema, S.J.; Naganawa, M.; Lu, Y.; Nabulsi, N.; Ropchan, J.; De Bruyn, S.; Otoul, C.; Stockis, A.; et al. Assessment of a white matter reference region for 11C-UCB-J PET quantification. Br. J. Pharmacol. 2019, 271678 19879230.
Koole, M.; Van Aalst, J.; Devrome, M.; Mertens, N.; Serdons, K.; Lacroix, B.; Mercier, J.; Sciberras, D.; Maguire, R.P.; Van Laere, K. Quantifying SV2A density and drug occupancy in the human brain using [11C]UCB-J PET imaging and subcortical white matter as reference tissue. Eur. J. Nucl. Med. Mol. Imaging 2018, 46, 396–406.
Varnäs, K.; Stepanov, V.; Halldin, C. Autoradiographic mapping of synaptic vesicle glycoprotein 2A in non-human primate and human brain. Synapse. 2020 doi:10.1002/syn.22157
Bretin, F.; Bahri, M.A.; Bernard, C.; Warnock, G.; Aerts, J.; Mestdagh, N.; Buchanan, T.; Otoul, C.; Koestler, F.; Mievis, F.; et al. Biodistribution and Radiation Dosimetry for the Novel SV2A Radiotracer [18F]UCB-H: First-in-Human Study. Mol. Imaging Boil. 2015, 17, 557–564.
Chen, M.K.; Mecca, A.P.; Naganawa, M.; Finnema, S.J.; Toyonaga, T.; Lin, S.F.; Najafzadeh, S.; Ropchan, J.; Lu, Y.; McDonald, J.W.; et al. Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging. JAMA Neurol. 2018, 75, 1215–1224.
Vanhaute, C.H.R.J.; Ceccarini, J.; Michiels, L.; Sunaert, S.; Lemmens, R.; Emsell, L.; Vandenbulcke, M.; Van Laere, K. Changes in Synaptic Density in Relation to Tau Deposition in Prodromal Alzheimer’s Disease: A Dual Protocol Pet-Mr Study. In Proceedings of the European Association of Nuclear Medicine 2019, EANM, Barcelona, Spain, October 2019; 46, S177–S178.
Finnema, S.J.; Rossano, S.; Naganawa, M.; Henry, S.; Gao, H.; Pracitto, R.; Maguire, R.P.; Mercier, J.; Kervyn, S.; Nicolas, J.; et al. A single-center, open-label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers. Epilepsia 2019, 60, 958–967
Matuskey, D.; Tinaz, S.; Wilcox, K.C.; Naganawa, M.; Toyonaga, T.; Dias, M.; Henry, S.; Pittman, B.; Ropchan, J.; Nabulsi, N.; et al. Synaptic Changes in Parkinson Disease Assessed with in vivo Imaging. Ann. Neurol. 2020, 87, 329–338
Bellucci, A.; Mercuri, N.B.; Venneri, A.; Faustini, G.; Longhena, F.; Pizzi, M.; Missale, C.; Spano, P. Review: Parkinson’s disease: from synaptic loss to connectome dysfunction. Neuropathol. Appl. Neurobiol. 2016, 42, 77–94
Onwordi, E.C.; Halff E.F.; Whitehurst T.; Mansur A.; Cotel M.C.; Wells L.; Creeney H.; Bonsall D.; Rogdaki M.; Shatalina E.; Reis Marques T.; Rabiner E. A.; Gunn R.N.; Natesan S.; Vernon A.C.; and Howes O.D. Synaptic Density Marker Sv2a Is Reduced in Schizophrenia Patients and Unaffected by Antipsychotics in Rats. Nat Commun. 2020, 11, 246.
Holmes S.E.; Scheinost D.; Finnema S.J.; Naganawa M.; Davis M.T.; DellaGioia N.; Nabulsi N.; Matuskey D.; Angarita G.A.; Pietrzak R.H.; Duman R.S.; Sanacora G.; Krystal J.H.; Carson R.E.; Esterlis I. Lower Synaptic Density Is Associated with Depression Severity and Network Alterations. Nature Communications. 2019, 10, 1529.